HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis
Abstract Background The national burden of human immunodeficiency virus treatment failure and associated factors in the Ethiopian context is required to provide evidence towards a renewed ambitious future goal. Methods We accessed Ethiopian Universities’ online repository library, Google Scholar, Pu...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-01-01
|
| Series: | BMC Public Health |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12889-020-8160-8 |
| _version_ | 1818670284558827520 |
|---|---|
| author | Aklilu Endalamaw Mengistu Mekonnen Demeke Geremew Fikadu Ambaw Yehualashet Hiwot Tesera Tesfa Dejenie Habtewold |
| author_facet | Aklilu Endalamaw Mengistu Mekonnen Demeke Geremew Fikadu Ambaw Yehualashet Hiwot Tesera Tesfa Dejenie Habtewold |
| author_sort | Aklilu Endalamaw |
| collection | DOAJ |
| description | Abstract Background The national burden of human immunodeficiency virus treatment failure and associated factors in the Ethiopian context is required to provide evidence towards a renewed ambitious future goal. Methods We accessed Ethiopian Universities’ online repository library, Google Scholar, PubMed, Web of Science, and Scopus to get the research articles. We run I-squared statistics to see heterogeneity. Publication bias was checked by using Egger’s regression test. The pooled prevalence was estimated using the DerSimonian-Laird random-effects model. We employed the sensitivity analysis to see the presence of outlier result in the included studies. Results The overall human immunodeficiency treatment failure was 15.9% (95% confidence interval: 11.6–20.1%). Using immunological, virological, and clinical definition, human immunodeficiency treatment failure was 10.2% (95% confidence interval: 6.9–13.6%), 5.6% (95% confidence interval: 2.9–8.3%), and 6.3% (95% confidence interval: 4.6–8.0%), respectively. The pooled effects of World Health Organization clinical stage III/IV (Adjusted Odd Ratio = 1.9; 95% CI: 1.3–2.6), presence of opportunistic infections (Adjusted Odd Ratio = 1.8; 95% CI: 1.2–2.4), and poor adherence to highly active antiretroviral therapy (Adjusted Odd Ratio = 8.1; 95% CI: 4.3–11.8) on HIV treatment failure were estimated. Conclusions Human immunodeficiency virus treatment failure in Ethiopia found to be high. Being on advanced clinical stage, presence of opportunistic infections, and poor adherence to highly active antiretroviral therapy were the contributing factors of human immunodeficiency virus treatment failure. Human immunodeficiency virus intervention programs need to address the specified contributing factors of human immunodeficiency virus treatment failure. Behavioral intervention to prevent treatment interruption is required to sustain human immunodeficiency virus treatment adherence. Protocol registration It has been registered in the PROSPERO database with a registration number of CRD42018100254. |
| first_indexed | 2024-12-17T07:05:40Z |
| format | Article |
| id | doaj.art-9eaceac2c4db409b9a8315fb4655a988 |
| institution | Directory Open Access Journal |
| issn | 1471-2458 |
| language | English |
| last_indexed | 2024-12-17T07:05:40Z |
| publishDate | 2020-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Public Health |
| spelling | doaj.art-9eaceac2c4db409b9a8315fb4655a9882022-12-21T21:59:11ZengBMCBMC Public Health1471-24582020-01-0120111210.1186/s12889-020-8160-8HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysisAklilu Endalamaw0Mengistu Mekonnen1Demeke Geremew2Fikadu Ambaw Yehualashet3Hiwot Tesera4Tesfa Dejenie Habtewold5Department of Pediatrics and Child Health Nursing, School of Health Sciences, College of Medicine and Health Sciences, Bahir Dar UniversityDepartment of Pediatrics and Child Health Nursing, School of Nursing, College of Medicine and Health Sciences, University of GondarDepartment of Immunology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of GondarDepartment of comprehensive nursing, School of Nursing, College of Medicine and Health Sciences, University of GondarStudent Clinic, Microbiologist, Bahirdar UniversityDepartment of Epidemiology, University of GroningenAbstract Background The national burden of human immunodeficiency virus treatment failure and associated factors in the Ethiopian context is required to provide evidence towards a renewed ambitious future goal. Methods We accessed Ethiopian Universities’ online repository library, Google Scholar, PubMed, Web of Science, and Scopus to get the research articles. We run I-squared statistics to see heterogeneity. Publication bias was checked by using Egger’s regression test. The pooled prevalence was estimated using the DerSimonian-Laird random-effects model. We employed the sensitivity analysis to see the presence of outlier result in the included studies. Results The overall human immunodeficiency treatment failure was 15.9% (95% confidence interval: 11.6–20.1%). Using immunological, virological, and clinical definition, human immunodeficiency treatment failure was 10.2% (95% confidence interval: 6.9–13.6%), 5.6% (95% confidence interval: 2.9–8.3%), and 6.3% (95% confidence interval: 4.6–8.0%), respectively. The pooled effects of World Health Organization clinical stage III/IV (Adjusted Odd Ratio = 1.9; 95% CI: 1.3–2.6), presence of opportunistic infections (Adjusted Odd Ratio = 1.8; 95% CI: 1.2–2.4), and poor adherence to highly active antiretroviral therapy (Adjusted Odd Ratio = 8.1; 95% CI: 4.3–11.8) on HIV treatment failure were estimated. Conclusions Human immunodeficiency virus treatment failure in Ethiopia found to be high. Being on advanced clinical stage, presence of opportunistic infections, and poor adherence to highly active antiretroviral therapy were the contributing factors of human immunodeficiency virus treatment failure. Human immunodeficiency virus intervention programs need to address the specified contributing factors of human immunodeficiency virus treatment failure. Behavioral intervention to prevent treatment interruption is required to sustain human immunodeficiency virus treatment adherence. Protocol registration It has been registered in the PROSPERO database with a registration number of CRD42018100254.https://doi.org/10.1186/s12889-020-8160-8HAARTHIVFailureTreatmentEthiopia |
| spellingShingle | Aklilu Endalamaw Mengistu Mekonnen Demeke Geremew Fikadu Ambaw Yehualashet Hiwot Tesera Tesfa Dejenie Habtewold HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis BMC Public Health HAART HIV Failure Treatment Ethiopia |
| title | HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis |
| title_full | HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis |
| title_fullStr | HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis |
| title_full_unstemmed | HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis |
| title_short | HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis |
| title_sort | hiv aids treatment failure and associated factors in ethiopia meta analysis |
| topic | HAART HIV Failure Treatment Ethiopia |
| url | https://doi.org/10.1186/s12889-020-8160-8 |
| work_keys_str_mv | AT akliluendalamaw hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis AT mengistumekonnen hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis AT demekegeremew hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis AT fikaduambawyehualashet hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis AT hiwottesera hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis AT tesfadejeniehabtewold hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis |